Staphylococcus aureus bacteremia: Difference between revisions

From IDWiki
Staphylococcus aureus bacteremia
()
()
Line 40: Line 40:
***Sterile follow-up blood cultures within 4 days from the initial set
***Sterile follow-up blood cultures within 4 days from the initial set
***No hemodialysis
***No hemodialysis
***Nosocomial acquisition of [[S. aureus]]
***Nosocomial acquisition
***Absence of secondary foci
***Absence of secondary foci
***No clinical signs of endocarditis
***No clinical signs of endocarditis

Revision as of 13:47, 6 February 2021

Background

Classification

  • Community-onset: positive blood culture obtained within 48 hours of presentation
  • Nosocomial: positive blood culture obtained after 48 hours of presentation

Etiology

  • IVDU
  • Poor dentition
  • Dental work

Clinical Manifestations

  • Often non-specific fevers and chills, diagnosed on blood cultures
  • May have back pain unrelated to spinal osteomyelitis
  • May present with focus of metastatic disease

Investigations

  • Repeat blood cultures every 24 to 48 hours until negative
  • Transthoracic echo (TTE) or transesophageal echo (TEE)

Management

  • Infectious diseases consultation
  • Must rule out endocarditis! TTE, followed by TEE if suspicion remains high (see PREDICT score)
    • Low risk for endocarditis (no TEE) if all of the following:
      • No intracardiac device
      • Sterile follow-up blood cultures within 4 days from the initial set
      • No hemodialysis
      • Nosocomial acquisition
      • Absence of secondary foci
      • No clinical signs of endocarditis
    • Uncomplicated if all of the following:
      • Endocarditis is excluded
      • No implanted prostheses
      • Blood cultures clear by 2-4 days
      • Defervesces within 72 hours
      • No evidence of metastases
      • +/- identified source has been removed
  • Two-week course acceptable if uncomplicated, otherwise 4-6 weeks
  • MSSA: cloxacillin 2g IV q4h for 2 weeks (cefazolin as an alternative)
  • MRSA: vancomycin 1g IV q12h for 2 weeks
    • Adjust based on serum trough before every fourth dose
    • Target trough 15-20

Prognosis

  • Mortality 20-50% at 30 days, 60% at 1 year
  • Mortality halved by ID consult
  • Prognosis worse with
    • Increased age
    • Female sex
    • Pneumonia or source unknown
    • Dementia
    • Increasing comorbidities
    • Shock at time of presentation
    • Institutionalized patient

Further Reading